Document is current

Article History

Received: 4 July 2022

Accepted: 19 September 2022

First Online: 13 October 2022

Declarations

:

: Not applicable.

: Not applicable.

: SR has received speaker fees from Zambon. DU and IB do not have competing interests to disclose. DvW receives speaker fees from Bial and Britannia pharmaceuticals, consultancy fees from Britannia and Invisio, research grants from CHDI, NIHR BRC, and Britannia. VL has received grants from NIHR BRC, Parkinson’s UK, travel and congress grants from Bial UK Ltd, speaker-related activities fees from Britannia pharmaceuticals, Bial UK, Profile, and consultancy fees from Invisio Pharmaceuticals and Bial UK, outside the submitted work. PO has received honoraria for advisory boards from: AbbVie, Bial, Britannia, Kyowa, Zambon; honoraria for lectures from: Bial, AbbVie, Bial, Britannia, Kyowa, Nordic Infucare, Stada, Zambon; Grants (Investigator initiated): Abbvie; Academic grants: Lund Medical Faculty, Multipark, Parkinsonfonden, Southern Swedish Health Care Region, Swedish Parkinson Academy, Åhlens. AJE has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Neuroderm, Neurocrine, Amneal, Acadia, Acorda, Bexion, Kyowa Kirin, Sunovion, Supernus (formerly, USWorldMeds), Avion Pharmaceuticals, and Herantis Pharma; personal compensation as honoraria for speakership for Avion; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics (a biotech start-up developing nonaggregating peptide analogues as replacement therapies for neurodegenerative diseases) and is co-owner of a patent that covers synthetic soluble nonaggregating peptide analogues as replacement treatments in proteinopathies. PJ receives honoraria for consultancies and advisory boards from Abbvie, BIAL, Britannia Pharmaceuticals, Celera, Eisai, FP Pharmaceuticals, Kyowa Kirin, Hoffman La Roche, Profile Pharma, UCB, Worldwide Clinical Trials, Zambon. KRC receives personal compensation as advisory board member from AbbVie, UCB, GKC, Bial, Cynapsus, Lobsor, Stada, Zambon, Profile Pharma, Synovion, Roche, Therevance, Scion, Britannia, Acadia, 4D Pharma (recent); Medtronic (2 years ago). Recent honoraria for lectures: AbbVie, Britannia, UCB, Zambon, Novartis, Boeringer Ingelheim, Bial, Kyowa Kirin, SK Pharma. Grants (Investigator Initiated): Bial (recent); Britannia Pharmaceuticals, AbbVie, UCB, GKC (over 2 years ago). Aacdemic grants: EU Horizon 2020, Parkinson's UK, NIHR, Parkinson’s Foundation, Wellcome Trust (recent); Kirby Laing Foundation, MRC (over 2 years ago). Royalties or licenses (ongoing): Oxford (book), Cambridge publishers (book), MAPI institute (KPPS, PDSS 2). Payment for expert testimony: GMC.